NASDAQ:BCRX
BioCryst Pharmaceuticals Stock News
$4.57
+0.440 (+10.65%)
At Close: May 01, 2024
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
02:43pm, Friday, 05'th Aug 2022 Benzinga
Upgrades
For 8x8 Inc (NYSE:EGHT), Craig-Hallum upgraded the previous rating of Hold to Buy. In the first quarter, 8x8 showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. At the moment
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
10:12am, Friday, 05'th Aug 2022 Benzinga
Gainers
ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per sh
BioCryst Pharmaceuticals (BCRX) Q2 2022 Earnings Call Transcript
08:00am, Friday, 05'th Aug 2022 The Motley Fool
BCRX earnings call for the period ending June 30, 2022.
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
08:00am, Friday, 05'th Aug 2022 Benzinga
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
ChemoCentryx, Inc. (NASDAQ: CCXI)
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
05:12pm, Thursday, 04'th Aug 2022 Benzinga
Gainers
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.
Onion Global Limited (NYSE: OG) gained 113.9% to $0.8556.
ChemoCentryx,
Options Bulls Blast Phama Stock on Lifted Clinical Hold
02:12pm, Thursday, 04'th Aug 2022
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is soaring today, last seen up 22.5% at $13.65, after the drug maker said the U.S. Food and Drug Administration (FDA) lifted a partial clinic hold on its blo
Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
02:12pm, Thursday, 04'th Aug 2022 The Motley Fool
The FDA has lifted the partial clinical hold on the biotech's kidney disease drug.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
12:35pm, Thursday, 04'th Aug 2022 Zacks Investment Research
BioCryst (BCRX) delivered earnings and revenue surprises of 11.11% and 2.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alibaba, MercadoLibre And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
11:59am, Thursday, 04'th Aug 2022 Benzinga
Global Blood Therapeutics, Inc. (NASDAQ: GBT) rose 19.3% to $40.47 in pre-market trading following a report suggesting the company is attracting takeover interest. According to a Bloomberg report, cit
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 Results - Earnings Call Transcript
11:28am, Thursday, 04'th Aug 2022
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants John Bluth - SVP, IR and Corporate Communications Jon Stonehouse - CEO Ant
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
11:00am, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
—Q2 2022 ORLADEYO net revenue of $65.2 million—
BioCryst Resumes Enrollment in BCX9930 Clinical Program
10:58am, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
—U.S. Food and Drug Administration lifts partial clinical hold— —U.S. Food and Drug Administration lifts partial clinical hold—
Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
10:12am, Thursday, 04'th Aug 2022
The FDA has lifted the partial clinical hold on the biotech's kidney disease drug.
3 Fast-Growing Stocks to Buy Now
01:00pm, Sunday, 31'st Jul 2022 The Motley Fool
ShockWave, Vir, and BioCryst are all seeing skyrocketing sales this quarter.
3 Fast-Growing Stocks to Buy Now
09:00am, Sunday, 31'st Jul 2022
ShockWave, Vir, and BioCryst are all seeing skyrocketing sales this quarter.
